Search the Newsreel

Stoke Therapeutics (STOK) CMO sells 7,176 shares under 10b5-1 plan

Stoke Therapeutics' Chief Medical Officer, Barry Ticho, sold 7,176 shares of common stock on August 3, 2026, under a Rule 10b5-1 trading plan adopted on November 19, 2025. The sales occurred in two transactions at weighted-average prices of $28.9501 and $29.4539 per share. Following …

Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates

Stoke Therapeutics reported its Q2 2026 financial results, highlighting significant progress in its clinical programs. The company completed enrollment for the Phase 3 EMPEROR study of zorevunersen for Dravet syndrome, with data expected in Q3 2027, and plans to initiate a rolling U.S. NDA …

Stoke: 'Buy' Zorevunersen NDA SCN1A DS And STK-002 Advancement (NASDAQ:STOK)

Stoke Therapeutics (STOK) maintains a "Buy" rating due to significant progress in its clinical programs. Key milestones include an expected FDA meeting in H2 2026 and a rolling NDA submission in Q1 2027 for zorevunersen in SCN1A Dravet Syndrome, with Phase 3 EMPEROR data …

UBS backs Rentokil after selloff, seeing 35% upside

UBS has reiterated its 'buy' rating for Rentokil Initial PLC (LSE:RTO) after a meeting with the pest control group's new chief executive, citing a sharply positive risk-reward skew following the recent selloff. The bank maintains its 480p price target, suggesting a 35% upside, despite …

Rentokil Initial PLC $RTO Shares Acquired by Bank of America Corp DE

Bank of America Corp DE significantly increased its stake in Rentokil Initial PLC (NYSE:RTO) during the first quarter, purchasing over 2.5 million additional shares, bringing their total holdings to 1.32% of the company. Rentokil Initial shares opened at $25.07, below their moving averages, and …

BofA Securities Initiates Rentokil Initial PLC(RTO.US) With Buy Rating

BofA Securities has initiated coverage on Rentokil Initial PLC (RTO.US) with a "Buy" rating. This indicates a positive outlook from the investment bank regarding the company's stock performance.

Rentokil Initial PLC (RTO) sells off as weekly volume surges

The move puts the specialty business-services group under renewed scrutiny after a sharp multiweek reset.

Stoke Therapeutics, Inc. Stock 12‑Month Price Target Cut to $45.64, Implies 54% Upside

Analysts have lowered the average 12-month price target for Stoke Therapeutics, Inc. (STOK) stock to $45.64 from $46.87, representing a potential 54% upside based on its August 3 closing price. Despite the cut, the consensus rating from 13 analysts remains a "Buy," with forecasts …

Enterprise value to revenue forward of Cytokinetics, Incorporated – BX:KK3A

This article displays the "Enterprise value to revenue forward" metric for Cytokinetics, Incorporated (BX:KK3A) on TradingView. It provides financial overview, documents, news, and community features related to the company. The page also includes various market data, tools, and community resources offered by TradingView.

Stoke Therapeutics (STOK) Stock Climbs As Cash Burn Meets Dravet Momentum

Stoke Therapeutics' stock rose 7% despite a widened net loss in Q2 2026, driven by positive momentum in its Phase III Dravet syndrome program. The company's cash position of US$420 million is expected to fund operations into the planned launch window, addressing investor concerns …

Rentokil Initial (NYSE: RTO) discloses Janus Henderson 4.99% voting stake

Rentokil Initial plc (NYSE: RTO) has reported via a TR-1 notification that Janus Henderson Group Limited and its controlled undertakings now hold a 4.995136% voting stake, totaling 126,179,117 voting rights. This position includes voting rights attached to shares and cash-settled CFDs, noting a slight …

Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC has announced an investigation into Cytokinetics, Incorporated (NASDAQ: CYTK) regarding potential corporate wrongdoing. The firm is encouraging shareholders who purchased Cytokinetics securities before December 27, 2023, and still hold them, to contact them to assist with the investigation. Bronstein, …

Wedbush Adjusts Price Target on Stoke Therapeutics to $40 From $38, Maintains Outperform Rating

Wedbush has increased its price target for Stoke Therapeutics (NASDAQ: STOK) to $40 from $38, while reiterating an Outperform rating on the stock. This adjustment follows recent company news, including the Q2 2026 earnings call and updates on their Phase 3 study for Dravet …

Stoke Therapeutics, Inc. Q2 2026: Revenue $9.3M, EPS $(0.93) — 10-Q Summary

Stoke Therapeutics, Inc. reported its Q2 2026 results, showing a decrease in revenue to $9.3M from $13.8M in Q2 2025, and a widened net loss of $(61.6M) with a diluted EPS of $(0.93). The company highlighted clinical progress for zorevunersen with Phase 3 trial …

Stoke outlines rolling NDA in Q1 2027 as $420M cash supports potential U.S. launch by early 2028

Earnings Call Insights: Stoke Therapeutics (STOK) Q2 2026 MANAGEMENT VIEW * "Starting with our Phase III EMPEROR study, the recent completion of enrollment of 162 patients in just 10 months speaks to the awareness and enthusiasm of zorevunersen" (CEO & Director Ian Smith). "We …

How Stoke Therapeutics Inc. (STOK) Affects Rotational Strategy Timing

This article analyzes Stoke Therapeutics Inc. (STOK) using AI models to provide trading strategies for different risk profiles and holding periods. It highlights divergent sentiment, support/resistance levels, and a favorable risk-reward setup for the stock. The analysis includes position trading, momentum breakout, and risk …

Tokyo Plast International Share Price Outlook: Where It Could Be in 3 Years

Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Rating of "Moderate Buy" by Analysts

Stoke Therapeutics (NASDAQ:STOK) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $43.00, despite recently missing earnings per share estimates while exceeding revenue forecasts. Insider sales by two executives under pre-arranged plans have been noted, though insiders …

Tolu Minerals (ASX:TOK): Gold and Copper Development Strategy Gains Market Attention

Rentokil Initial PLC (RTO) breaks lower as weekly pressure broadens

Heavy turnover and weak momentum readings show the decline is being confirmed beyond price alone.

Stoke Therapeutics (NASDAQ:STOK) Issues Quarterly Earnings Results, Misses Estimates By $0.13 EPS

Stoke Therapeutics reported a quarterly loss of $0.93 per share, missing analyst estimates by $0.13, despite revenue of $9.32 million exceeding expectations. The company remains unprofitable, but its shares rose by $0.70 to $29.56 following the announcement. Analysts maintain a "Moderate Buy" consensus with …

Earnings Flash (STOK) Stoke Therapeutics, Inc. Reports Q2 Revenue $9.3M, vs. FactSet Est of $4.9M

Stoke Therapeutics (NASDAQ: STOK) swings to H1 2026 loss as revenue falls

Stoke Therapeutics reported a significant financial downturn in H1 2026, swinging to a net loss of $111.6 million compared to a net income of $89.4 million in H1 2025, primarily due to a sharp decline in revenue from $172.4 million to $15.6 million. This …

Stoke's Dravet trial enrolls 162; data readout anticipated Q3 2027

Stoke Therapeutics announced the completion of enrollment for its Phase 3 EMPEROR study of zorevunersen in Dravet syndrome, with 162 patients enrolled and a data readout expected in Q3 2027. The company is preparing for a rolling U.S. NDA submission to begin in Q1 …

Earnings call transcript: Stoke Therapeutics posts Q2 2026 revenue beat as Dravet drug advances

Stoke Therapeutics reported a wider-than-expected Q2 2026 loss but significantly beat revenue forecasts, driven by the advancement of its Dravet syndrome drug, zorevunersen, towards a potential U.S. launch in early 2028. The company's Phase III EMPEROR study has exceeded enrollment targets with no patient …

Deutsche Bank Aktiengesellschaft Issues Pessimistic Forecast for Rentokil Initial (LON:RTO) Stock Price

Deutsche Bank Aktiengesellschaft has reduced its price target for Rentokil Initial (LON:RTO) from GBX 465 to GBX 405, while maintaining a "hold" rating, suggesting a potential upside of 17.7%. Other analysts have also adjusted their targets, yet the overall sentiment remains a "Moderate Buy" …

Rentokil Initial (NYSE: RTO) directors and CEO-linked accounts buy shares

Rentokil Initial plc reported that its CEO, Mike Duffy, acquired 10,500 American Depositary Shares (ADSs) through a joint account. Additionally, a trust associated with Chair Designate Thérèse Esperdy bought 21,214 ADSs, and Non-Executive Director Leanne Sheraton purchased 10,000 ordinary shares. These transactions, which took …

Rentokil Initial rises Monday, outperforms market

Shares of Rentokil Initial PLC (RTO) rose 3.48% on Monday, closing at £3.57, despite an overall market downturn where the FTSE 100 Index (UKX) fell 0.10%. The company's stock is currently 29.63% below its 52-week high of £5.07, which it reached on April 15th.

CYTK|Cytokinetics Inc|Price:78.690|Chg%:+2.240

Cytokinetics Inc (CYTK) exhibits weak fundamentals but high growth potential, with its valuation considered fairly priced within the Biotechnology & Medical Research industry. Institutional ownership is very high, and analysts have consistently rated it as a "Buy" with a target price of $108.47. Despite …

Tokyo Plast Consolidated June 2026 Net Sales at Rs 19.83 crore, up 8.9% Y-o-Y

Stoke Therapeutics faces earnings test as Dravet drug awaits data

Stoke Therapeutics earnings missed by $0.16, revenue topped estimates

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Half Year 2026 Rentokil Initial PLC Earnings Call Transcript

This article provides the transcript of Rentokil Initial PLC's Half Year 2026 Earnings Call. Key positive points highlighted include a 4.5% revenue increase, 6.6% operating profit rise, improved free cash flow conversion to 96%, and reduced leverage to 2.4x. Negative points mention slowed North …

Rentokil Initial (RTO.L) Stock Analysis: Exploring a 44% Potential Upside Amidst Robust Revenue Growth

Stoke Therapeutics, Inc. $STOK Shares Acquired by Janus Henderson Group PLC

Janus Henderson Group PLC increased its stake in Stoke Therapeutics (NASDAQ:STOK) by 11.2% in the first quarter, now owning over 1.6 million shares valued at approximately $52.5 million. Despite a quarterly loss, analyst sentiment remains positive with a "Moderate Buy" consensus rating and an …